Last checked at 14 Jun 2012 07:00
EDEN RESEARCH PLC
("Eden" or "Company")
Director's Dealing
Eden Research plc (AIM: EDEN), the agrochemical and encapsulation development company, has been notified that, on 13 June 2012, Sir Ben Gill, Non Executive Chairman of the Company, acquired 187,000 ordinary shares of 1p each in the Company, at a price of 13p per share. Following this purchase Sir Ben has a beneficial interest in 656,181 ordinary shares representing approximately 0.59 per cent. of the Company's issued share capital.
Eden has also been notified that on 13 June 2012, Kenneth Brooks, Executive Deputy Chairman of the Company, acquired 190,000 ordinary shares of 1p each in the Company, at a price if 12.92p per share. Following this purchase Mr Brooks has a beneficial interest in 1,688,192 ordinary shares representing approximately 1.52 per cent. of the Company's issued share capital.
Eden Research plc | www.edenresearch.com |
Clive Newitt, Managing Director | Tel: 01993 862 761 |
Alex Abrey, Chief Financial Officer | |
Zeus Capital Limited | Tel: 0161 831 1512 |
Ross Andrews, Andrew Jones | |
Walbrook PR Ltd | Tel: 020 7933 8780 |
Paul McManus (Media Relations) | Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com |
Paul Cornelius (Investor Relations) | Mob: 07827 879 496 or paul.cornelius@walbrookir.com |
Capitalised terms in this announcement are as defined in the Company's Admission document, which is available on the Company's website: www.edenresearch.com
Notes:
Eden is an early stage revenue company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions to the global agrochemicals industry, the animal health industry, and consumer products.
Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with hydrophobic compounds both natural and synthetic. The technology uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.
Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.
With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.
The Company has a number of patents and has a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property. Revenues earned by the Company have been modest (2010: £172,000; 2011: £91,000) whilst the Company has concentrated on securing patent protection for its intellectual property, identifying suitable industrial partners and entering into licence agreements.
Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.
For more information about Eden, please visit www.edenresearch.com